Age-dependent Effects of Flavanols on Vascular Status
- Conditions
- Cardiovascular Diseases
- Interventions
- Dietary Supplement: Flavanol rich interventionDietary Supplement: Flavanol free control
- Registration Number
- NCT01639781
- Lead Sponsor
- Heinrich-Heine University, Duesseldorf
- Brief Summary
Epidemiological studies suggest that certain foods rich in flavanols, including cocoa products, red wine, and tea, are associated with decreased cardiovascular mortality and morbidity. Dietary interventional studies have corroborated this finding and showed that flavanols can acutely and after sustained ingestion improve surrogate markers of cardiovascular risk including endothelial function. Endothelial dysfunction is the key event in the development and progression of cardiovascular disease. Aging is the major non-modifiable cardiovascular risk factor associated with progressive decline in endothelial function, vascular stiffening and increase in blood pressure. We hypothesize that flavanols can counteract age-dependent vascular changes by interacting with key mechanisms, most prominently endothelial function.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 44
- healthy male participants between 18-35 years
- healthy male participants between 50-80 years
- acute inflammation
- cardiac arrhythmia
- renal failure
- heart failure (NYHA II-IV)
- diabetes mellitus
- CRP > 1 mg/dl
- malignant disease
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description flavanol rich intervention Flavanol rich intervention flavanol rich drink flavanol free intervention Flavanol free control flavanol free drink
- Primary Outcome Measures
Name Time Method Endothelial function change in flow mediated dilatation between first treatment at day 0 and after last treatment at day 14 Flow mediated dilatation (FMD)
- Secondary Outcome Measures
Name Time Method NO bioavailability 14 days Measured by CLD
Pulse wave velocity 14 days Measured by SphygmoCor
Erythrocyte deformability 14 days Measured by Laser-assisted Optical Rotation Cell Analyzer (LORCA)
Ambulatory blood pressure blood pressure at day 0 and at day 14 automatical measurements
Heart rate 14 days Measured by ECG
Plasma flavanol metabolites analysis of metabolites between first treatment at day 0 and after last treatment at day 14 Measured by HPLC
Microvascular function 14 days Measured by Laserdoppler perfusion imaging (LDPI)
Augmentation index 14 days Measured by SphygmoCor
Trial Locations
- Locations (1)
Division of Cardiology, Pulmonology and Vascular Medicine
🇩🇪Duesseldorf, NRW, Germany